A new medical test developed by Renatek, a Japanese company, is now available at Ichikawa Clinic in Yokohama. The test, called the Metal Balance Test, uses just 6 milliliters of blood to evaluate the risk of cancer and mild cognitive impairment (MCI). The service began accepting appointments in December.
The test analyzes the balance of metals in the blood to identify potential health risks. It is designed to detect early signs of cancer and cognitive decline. The test is part of Renatek's efforts to improve early diagnosis and preventive healthcare.
Renatek has been working on this technology for several years, focusing on the role of metal levels in the body. The company has conducted extensive research and clinical trials to validate the accuracy of the test. This new service is the result of that research and aims to provide a more accessible and efficient way to monitor health risks.
